Arcutis Biotherapeutics Inc (ARQT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Arcutis Biotherapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 25.90 $ — 69% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% 31.2%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 31.2%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -9.2%
- ROCE > 15% -4.0%
- Expected return > 10% 30.9%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 367.1% passed
- More than 10% revenue growth is expected for the coming year 29.9% passed
- Share count grows by less than 3% a year 32.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 89.7% passed
- Gross margin at 40% or higher and without meaningful erosion 90.2% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 215 m net cash passed
- Operating cash flow covers the profits of the last three years 53 m failed
- Return on capital at 15% or higher, or up versus two years ago -4.0% failed
- Insiders hold at least 10% or are net buyers 1.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 33.7% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.18 | -0.05 – 0.33 | 500 | 235.9% | 6 |
| 12/31/2027 | 1.13 | 0.79 – 1.61 | 647 | 541.5% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.09 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.09 | – | 71 | 427.60 | -15.10 | -1 | -6 |
| 2025: Q1 | -0.20 | – | 66 | 32.80 | -38.10 | -30 | -31 |
| 2025: Q2 | -0.13 | – | 82 | 164.10 | -19.50 | 0 | 0 |
| 2025: Q3 | 0.06 | – | 99 | 121.70 | 7.50 | -2 | -2 |
| 2025: Q4 | 0.13 | – | 130 | 81.50 | 13.40 | 26 | 26 |
| 2026: Q1 | -0.09 | – | 105 | 60.10 | -10.70 | 2 | 2 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 0 | -4 | -5 | -4.71 | -4 | -5 | 4 |
| 2018 | 0 | -20 | -19 | -0.53 | -14 | -24 | 51 |
| 2019 | 0 | -43 | -42 | -1.10 | -43 | 101 | 107 |
| 2020 | 0 | -137 | -136 | -3.80 | -113 | 271 | 298 |
| 2021 | 0 | -207 | -206 | -4.17 | -175 | 298 | 408 |
| 2022 | 4 | -302 | -311 | -5.66 | -258 | 210 | 449 |
| 2023 | 60 | -241 | -262 | -3.78 | -247 | 89 | 341 |
| 2024 | 197 | -128 | -140 | -1.16 | -112 | 158 | 349 |
| 2025 | 376 | -12 | -16 | -0.13 | -6 | 189 | 433 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Arcutis Biotherapeutics, Inc., ein biopharmazeutisches Unternehmen, konzentriert sich auf Entwicklung und Vermarktung von Behandlungen für dermatologische Erkrankungen.
| Employees | 354 |
|---|---|
| Headquarters | Westlake Village, CA |
| Address | 3027 Townsgate Road, 91361 Westlake Village, United States |
| Phone | 805 418 5006 |
| Website | arcutis.com |
| IPO Date | 31. Jan 2020 |
| ISIN | US03969K1088 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Todd Franklin Watanabe M.A. | President, CEO & Director | 1968 |
| Bhaskar Chaudhuri Ph.D. | Co-Founder & Director Emeritus | 1955 |
| Latha Vairavan | Senior VP & Chief Financial Officer | 1978 |
| Masaru Matsuda Esq., J.D. | Executive VP, Chief Legal Officer & Corporate Secretary | 1971 |
| Patrick E. Burnett M.D., Ph.D. | Executive VP & Chief Medical Officer | 1972 |
| Larry Todd Edwards | Executive VP & Chief Commercial Officer | 1964 |
| Brian Schoelkopf | Head of Investor Relations | – |
| Steve Arias | Vice President of Compliance & Privacy | – |
| Amanda Sheldon | Head of Corporate Communications | – |
| Aleen Hosdaghian | Vice President of Marketing | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Peetz Christopher | Director | Other | 4,315 | 0.00 | – |
| 15. Jul 2026 | Welgus Howard G. | Director | Sell | 4,730 | 26.91 | 127,284 |
| 15. Jul 2026 | Welgus Howard G. | Director | Other | 2,255 | 8.63 | 19,461 |
| 15. Jul 2026 | Welgus Howard G. | Director | Other | 1,019 | 7.51 | 7,653 |
| 15. Jul 2026 | Welgus Howard G. | Director | Other | 822 | 6.52 | 5,361 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.